The subsequent heightened interest in a new therapeutic agent for DM culminated in the discovery of the first GLP-1 analogue, exenatide, which was approved by the US FDA for the treatment of type 2 diabetes mellitus (T2DM) in 2005 [11]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.